GlassScriptPhysician profile
Surya Abraham
NPI 1780105312
$3,950.15
in general payments reported to CMS, 2019-2025
25 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $892 · 2022: $1,104 · 2023: $560 · 2024: $329 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $508.65 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $463.55 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $446.80 | 2021-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $406.00 | 2021-2022 | |
| Abbvie INC. | $359.84 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $297.79 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $199.60 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.90 | 2021-2025 | Caplyta |
| Corium, LLC | $171.40 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $154.04 | 2022-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $128.71 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $101.98 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $99.32 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $89.22 | 2021-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $58.41 | 2025 | Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $45.68 | 2022-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $43.68 | 2021-2022 | |
| Globus Medical, INC. | $37.50 | 2021 | |
| Merck Sharp & Dohme LLC | $35.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.57 | 2022 | |
| Brainsway USA INC | $22.42 | 2023 | |
| Collegium Pharmaceutical, INC. | $21.06 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $19.69 | 2023 | Aplenzin |
| Aytu Biopharma, INC. | $15.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surya Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.